Aletta® brings automation to the preanalytical phase
Aletta®, the first Autonomous Robotic Phlebotomy Device™ (ARPD™), is designed to automate blood collection, helping laboratories managing growing sample volumes and workforce challenges.
Consistent sample quality
Aletta® is designed to standardize blood draws, reducing preanalytical variation and ensuring quality across samples.
Streamlined laboratory workflow
By automating blood draws, Aletta® aims to reduce workload and improve efficiency of the laboratory workflow.
Sustainable capacity
Aletta® is designed to support laboratories that face staff shortages and increasing sample volumes.
How does Aletta® work?
Aletta automates venipuncture procedures, aiming to standardize the blood collection process. Operating alongside manual draw stations, it performs routine blood draws autonomously.
Using advanced multimodal imaging, combining near-infrared and ultrasound, Aletta identifies a suitable vein. In addition, Aletta uses Doppler ultrasound to distinguish arteries from veins. Aletta will only proceed with the venipuncture once a suitable vein is identified.
Every blood collection with Aletta follows the same controlled procedure. First, the device applies the tourniquet, followed by vein selection. Then, Aletta performs the venipuncture with submillimeter accuracy, fills and inverts the tubes, and applies a bandage.
Aletta is designed to reduce preanalytical variability and support consistent quality across all samples. For example, tube inversion and handling are standardized within the device, aiming to minimize factors that can influence hemolysis or downstream analysis.
One trained supervisor can oversee up to three devices and assist patients when needed. This supervisor model is designed to increase capacity and relieve pressure on phlebotomy teams without changing analytical procedures or result interpretation processes.
Proven clinical performance and safety
Safe by design
Aletta® uses a new sterile needle for each procedure. The device uses Doppler ultrasound for vein confirmation and will only attempt venipuncture once a suitable vein is found.
Every step of the procedure is standardized, ensuring consistent collection conditions and minimizing the risk of preanalytical variation.
Clinically validated performance
The performance of Aletta is evaluated in the premarket ADOPT trial (NCT05878483), conducted across four Dutch hospitals. In April 2026, results from the clinical trial were published in Clinical Chemistry, evaluating performance, safety and patient experience in outpatient daily clinical use. Aletta achieved a first-stick success rate of 94.5% and an hemolysis rate of 0.3%, with no moderate or serious adverse events . 90% of patients reported they experienced less or comparable pain to a manual blood draw1.
Reliable across patient populations
Aletta® can draw blood from most patients aged sixteen and older, regardless of skin color or body composition. Its combination of near-infrared, ultrasound, and Doppler ultrasound imaging allows accurate vein detection across all skin tones and body types.
Our clinical partners
Customer Success
Implementation and training
Patient education and engagement
Technical and professional services
Let's get in touch
Do you have questions or want to learn more about Aletta®? Our team is ready to help you explore how Aletta can support your laboratory and improve patient care.
See Aletta® in action: Experience automated blood collection
¹ Giesen, L.F.P., Roest, J.A., et al. Performance, Safety, and Patient Experience of an Autonomous Robotic Phlebotomy Device: A Multicenter Trial. Clinical Chemistry (2026)
Note: this study evaluated an investigational version of the device. The results have not been reviewed by regulatory authorities.